A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor
Research Grant
Administered By
Duke Cancer Institute
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
July 1, 2015
End Date
January 31, 2023
Administered By
Duke Cancer Institute
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
July 1, 2015
End Date
January 31, 2023